Therapeutic resistance | Mechanisms | Cancer types | M6A regulators | Roles | Functions | Ref. |
---|---|---|---|---|---|---|
Chemoresistance | Drug transport | CRC | IGF2BP3↑ | ABCB1↑ | Doxorubicin resistance | [60] |
HCC/breast cancer | METTL3↑ | ERRγ↑ → ABCB1↑ | Doxorubicin resistance | [61] | ||
breast cancer | YTHDF2↓ | ATF3↑ → ABCB1↑ | Tamoxifen resistance | [62] | ||
Autophagy | GC | FTO↑ | mTORC1 signal pathway↓ | 5-Fu/cisplatin/paclitaxel resistance | [63] | |
Seminoma | METTL3↑ | ATG5↑ | Cisplatin resistance | [64] | ||
DNA damage repair | CSCC | FTO↑ | β-catenin↑ → ECCR1↑ | Cisplatin resistance and radioresistance | [13] | |
breast cancer | YTHDC1↑ | BRCA1/RAD51↑ | Adriamycin resistance | [65] | ||
seminoma | METTL3/IGF2BP1↑ | TFAP2C↑ → WEE1/BRCA1 ↑ | Cisplatin resistance | [66] | ||
EMT and CSCs | CC | METTL3/IGF2BP1↑ | CBX8↑ → LGR5↑ | Oxaliplatin resistance | [67] | |
CRC | METTL3↑ | Sec62↑ → Wnt/β-catenin signaling↑ | 5-Fu/oxaliplatin resistance | [68] | ||
Glycolysis | BC | ALKBH5↓ | CK2α↑ | Cisplatin resistance | [69] | |
GBM | FTO↑ | PDK1↑ | Temozolomide resistance | [70] | ||
Radioresistance | DNA damage repair | LUAD | IGF2BP2/3↑ | VANGL1↑ → BRAF/TP53BP1/RAD51 pathway↑ | Radioresistance | [71] |
EMT and CSCs | ESCC | METTL14↓ | miR-99a-5p↓ → TRIB2↑ | Radioresistance | [72] | |
Targeted therapy resistance | Drug transport | NSCLC | FTO↑ | ABCC10↑ | Gefitinib resistance | [12] |
HCC | METTL14↓ | HNF3γ↓ → OATP1B1/3↓ | Sorafenib resistance | [73] | ||
Apoptosis | leukemia | FTO↑ | BCL-2↑ | TKIs resistance | [14] | |
Immunotherapy resistance | TME | – | METTL3↓ | M1/M2-like TAM/Treg infiltration↑ | Anti-PD-1 therapy resistance | [74] |
melanoma | ALKBH5↑ | Tregs/MDSCs accumulation↑ | Anti-PD-1 therapy resistance | [75] | ||
ICC | ALKBH5↓ | PD-L1 ↓ | Anti-PD-1/PD-L1 therapy resistance | [76] | ||
CRC and melanoma | METTL3/14↑ | CD8+ T cells/CXCL9/CXCL10 ↓ | Anti-PD-1 therapy resistance | [77] |